#BDRX Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP

#BDRX Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP
#BDRX Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
#BDRX Interim results for the six months ended June 30, 2026